At Pacira, we understand that business partnerships can help us achieve mutual goals of developing and delivering innovative new therapies to improve patient care. We are well-positioned as a partner of choice given our financial strength, deep clinical and commercial expertise in the hospital and ambulatory markets, significant partnership network, and proven track record for improving market access to opioid-sparing strategies. As we look ahead, we remain committed to collaborations with like-minded partners who share our commitment to minimizing the use of opioids.
The potential benefits of pMVL have attracted partners pursuing reformulations of product candidates with significant market potential. We are developing new formulations of traditional small molecule and biologic therapies to build a pipeline of commercial opportunities for proprietary pursuit, as well as for out-licensing. For partners, this approach may provide a low risk clinical and regulatory development opportunity.
To inquire about our pMVL technology, please contact our Business Development team at email@example.com.
Pacira owns all product rights to EXPAREL for human use in all markets. Aratana owns animal rights for bupivacaine liposome injectable suspension in all markets. Nuance owns exclusive rights to develop and commercialize EXPAREL in China. As such, we believe the global potential for EXPAREL use in the management of postsurgical pain presents a large addressable market opportunity.
As Pacira continues to expand its pipeline and capabilities to serve more patients worldwide, our business development team evaluates partnering and investment opportunities with the potential to advance the development and delivery of breakthrough medical innovations.
We invite companies and researchers who share our purpose and sense of urgency to contact Pacira to discuss partnership opportunities.
The Pacira Global Procurement and Strategic Sourcing teams support business colleagues in facilitating a rigorous process of selecting vendors in a variety of spend areas including: Research and Development, Clinical Operations, Professional Services, IT, Travel Services, Contingent Workforce, Direct Materials-Manufacturing, Supply Chain-Distribution, and Real Estate and Facilities Management. Pacira and its subsidiaries are committed to conducting business in an ethical, legal, and socially responsible manner.